Related Experiment Videos
[Cyclophosphamide therapy in systemic lupus erythematosus]
1Universitätsklinikum Charité, Medizinische Universitätsklinik, Berlin.
Zeitschrift Fur Rheumatologie
|July 1, 1997
Summary
Intravenous cyclophosphamide bolus therapy is effective for severe Systemic Lupus Erythematosus (SLE), particularly lupus nephritis. However, due to significant malignancy risks, cautious use and specialized hospital administration are crucial.
Area of Science:
- Immunology
- Pharmacology
- Nephrology
Context:
- Systemic Lupus Erythematosus (SLE) frequently involves renal and central nervous system complications.
- Lupus nephritis poses a significant risk of renal failure.
- Intravenous cyclophosphamide bolus therapy has emerged as a standard treatment for severe SLE.
Purpose:
- To review the efficacy and side effects of cyclophosphamide in SLE treatment.
- To analyze recent clinical studies on cyclophosphamide bolus therapy.
- To highlight the risks associated with cyclophosphamide use, particularly long-term cumulative effects.
Summary:
- Cyclophosphamide is a key immunosuppressant for SLE, especially for preventing lupus nephritis progression.
- Intravenous cyclophosphamide bolus therapy offers higher efficacy and fewer side effects than oral administration for severe SLE.
- While oral cyclophosphamide is explored for cost-effectiveness, long-term data are lacking.
Impact:
- Cyclophosphamide bolus therapy demonstrates significant benefits in managing severe SLE manifestations.
- The risk of malignancies increases substantially with cumulative doses around 60g, necessitating careful patient monitoring.
- Administration of cyclophosphamide bolus therapy should be restricted to experienced hospital settings due to potential adverse events.